Researchers analyzed 19 human colorectal tumors with genome sequencing technologies and simulation models.
Here’s what they found.
1. Malignant tumors had abnormal cell movement in nine of 15 invasive samples. The movements were evident upon creation of the tumors.
2. Of the four benign tumors, none had early abnormal cell movement.
3. Durham, N.C.-based Duke University’s Marc Ryser, PhD, said, “We found evidence that benign and malignant tumors start differently, and that cell movement — an important feature of malignancy — manifests itself very early on during tumor growth.”
4. Researchers said more research was needed on a larger scale, but the findings were a significant step. They hope the findings could be used to develop a test that distinguished between deadly and harmless growths more easily.
More articles on gastroenterology:
President Trump vows to ‘bring soaring drug prices back down to earth’ — 6 takeaways
4 new joint venture ASCs and partnerships — April/May 2018
Envision ponders sale & more — 9 ASC company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
